EXFORGE Drug Patent Profile

Which patents cover Exforge, and what generic alternatives are available?

Exforge is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in EXFORGE is amlodipine besylate; hydrochlorothiazide; valsartan. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

Summary for EXFORGE

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	15
Drug Prices:	Drug price information for EXFORGE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXFORGE
What excipients (inactive ingredients) are in EXFORGE?	EXFORGE excipients list
DailyMed Link:	EXFORGE at DailyMed

See drug prices for EXFORGE

See drug sales revenues for EXFORGE

Recent Clinical Trials for EXFORGE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
International Bio service	Phase 1
Novartis Pharmaceuticals	Phase 4
Hanlim Pharm. Co., Ltd.	Phase 1

See all EXFORGE clinical trials

Pharmacology for EXFORGE

Drug Class	Angiotensin 2 Receptor Blocker Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists Cytochrome P450 3A Inhibitors

Paragraph IV (Patent) Challenges for EXFORGE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXFORGE	Tablets	amlodipine besylate; valsartan	5 mg/320 mg	021990	1	2007-11-26
EXFORGE	Tablets	amlodipine besylate; valsartan	10 mg/320 mg	021990	1	2007-11-09
EXFORGE	Tablets	amlodipine besylate; valsartan	5 mg/160 mg	021990	1	2007-10-22
EXFORGE	Tablets	amlodipine besylate; valsartan	10 mg/160 mg	021990	1	2007-10-01

US Patents and Regulatory Information for EXFORGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXFORGE	amlodipine besylate; valsartan	TABLET;ORAL	021990-002	Jun 20, 2007	AB	RX	Yes	No
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-003	Apr 30, 2009	AB	RX	Yes	No
Novartis	EXFORGE	amlodipine besylate; valsartan	TABLET;ORAL	021990-005	Jun 20, 2007	AB	RX	Yes	Yes

Expired US Patents for EXFORGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	EXFORGE	amlodipine besylate; valsartan	TABLET;ORAL	021990-005	Jun 20, 2007
Novartis	EXFORGE	amlodipine besylate; valsartan	TABLET;ORAL	021990-002	Jun 20, 2007
Novartis	EXFORGE	amlodipine besylate; valsartan	TABLET;ORAL	021990-003	Jun 20, 2007

International Patents for EXFORGE

See the table below for patents covering EXFORGE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	134624
Australia	644844
Australia	7115191

Supplementary Protection Certificates for EXFORGE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	91347	Luxembourg		91347, EXPIRES: 20160212
0443983	C00443983/02	Switzerland		PRODUCT NAME: VALSARTAN UND AMLODIPIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57771 22.12.2006
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016

EXFORGE (amlodipine/valsartan) market dynamics and financial trajectory: sales, payer positioning, generic and biosimilar risk, and revenue exposure

Last updated: July 29, 2026

EXFORGE (amlodipine besylate/valsartan) generated meaningful early franchise revenue as a branded fixed-dose combination for hypertension, but its long-term financial trajectory is dominated by (1) post-launch generic erosion across the combination and component markets and (2) payer-driven substitution to lower-cost angiotensin receptor blocker plus calcium channel blocker (ARB+CCB) regimens, including other branded and authorized generics. The remaining revenue outlook is tied to how quickly combination-generic penetration accelerates versus the persistence of branded co-pay programs and formulary placement in commercially insured lives.

How did EXFORGE perform financially after launch?

EXFORGE is an established ARB+CCB fixed-dose combination product. Its sales profile follows the typical branded hypertension pattern: growth through formulary access after launch, followed by sustained pressure from combination generics and aggressive payer steering to inexpensive equivalents.

Financial trajectory drivers (high level):

• Formulary placement and tier position after national and payer contracting.
• Net price compression as generics entered and PBMs revised preferred lists.
• Switching friction: adherence may improve versus separate tablets, but switching to generic combination tablets is usually straightforward once available.
• Component-level substitution: even when payers resist branded combination switches, cheaper generic amlodipine plus generic valsartan remains available.

What typically determines EXFORGE’s net sales decline rate in ARB+CCB:

• Speed of generic combination uptake (vs separate generic components).
• Copay card effectiveness and payer carve-outs (commercial plans).
• Medicare coverage dynamics after entry of combination generics and authorized generics.

What market dynamics shape EXFORGE demand in hypertension?

Hypertension is a high-volume, high-competition chronic market where PBMs steer toward lowest-cost effective therapy, and prescribers shift based on formulary status, patient tolerability, and dosing simplicity.

What payer behaviors drive competition for ARB+CCB fixed-dose combinations?

• Step edits and formulary tiers: ARB+CCB combinations often become non-preferred once combination generics are available.
• Use of preferred ARBs and CCBs: payers prefer specific ARB and CCB molecules, but fixed-dose combinations often lose branding value as generic equivalents expand.
• Therapeutic interchange: clinicians frequently treat ARB+CCB as a class interchange where product selection depends on copays and pill burden.

How do patient adherence and dosing affect EXFORGE persistence?

• Fixed-dose combinations reduce pill burden and may improve persistence versus free-dose titration.
• Once generic combination dosing is available, adherence advantages can shift to lower-cost equivalents.

When did generic erosion likely begin for EXFORGE and how does that affect revenue?

EXFORGE faces rapid revenue pressure once fixed-dose combination generic products enter, because payers and patients can switch to therapeutically equivalent alternatives with minimal clinical risk.

Generic entry risk is highest for fixed-dose combination brands

For ARB+CCB products, combination generics typically:

• Capture prescriptions quickly after launch,
• Compress net price across the branded product through PBM formulary updates,
• Reduce the value of branded co-pay programs as patient out-of-pocket costs fall.

Revenue exposure mechanics

• Gross-to-net compression accelerates post generic entry due to rebates, patient assistance, and contracting.
• Volume loss occurs as prescribers move to preferred generic NDCs.
• Remaining branded demand is often concentrated in:
  • patients already stable on EXFORGE but not switched by clinicians,
  • settings where generic substitution is delayed by operational barriers.

Which competing ARB+CCB products most affect EXFORGE’s share?

EXFORGE competes against other ARB+CCB fixed-dose combinations and the broader set of ARB plus CCB regimens delivered as separate tablets.

Competitive comparison: branded fixed-dose ARB+CCB vs generic alternatives

Key competitive pressures tend to come from:

• Other branded ARB+CCB fixed-dose combinations with better payer positioning at the time of contracting.
• Combination-authorized generics or fully generic fixed-dose products once multiple suppliers enter.
• Separate generic dosing of valsartan (or alternative ARB) plus amlodipine (or alternative CCB), which erodes fixed-dose premium value.

What does the Orange Book status imply for EXFORGE exclusivity and generic entry timelines?

Exclusivity and patent status determine when combination generics can launch and whether launch can proceed via paragraph IV or other pathways. For an established ARB+CCB brand like EXFORGE, the competitive reality is usually that patent and exclusivity barriers have already fallen away for most relevant product features (composition, formulation, and method-of-use claims vary by jurisdiction and patent portfolio).

Impact on commercialization:

• If exclusivity has lapsed, generic manufacturers can rely on legal and regulatory pathways to launch combination products.
• If remaining patents cover narrower attributes (for example, specific formulation types), the brand may see temporary niche protection, but payer substitution generally still advances once “good enough” generic options are available.

How strong is the patent estate for EXFORGE versus other ARB+CCB combinations?

For older fixed-dose cardiovascular combination products, patent strength tends to be less of a long-run protective lever because:

• combination products usually face multiple patent generations,
• generic launch opportunities often increase through incremental ANDA submissions,
• courts and settlement agreements frequently result in earlier practical market entry than initial theoretical expiration dates.

What to expect in practice for EXFORGE:

• Any residual patent coverage typically slows entry of specific generic formats, not the broader ability of payers to substitute.
• Revenue impact from litigation outcomes usually manifests as differences in launch date by months to a few years, not decades, in mature hypertension markets.

What Paragraph IV and litigation dynamics matter for EXFORGE?

In mature combination products, paragraph IV actions and related litigation usually:

• determine specific generic launch triggers,
• influence “at-risk” launch schedules,
• shape settlement-based entry timing.

Commercial relevance:

• Even when litigation delays entry for one applicant, subsequent ANDA filers often accelerate generic competition through later launches.
• Settlement typically results in a predictable erosion path, compressing net price and volume faster than brand teams expect.

What does FDA regulatory status imply for EXFORGE’s competitive positioning?

FDA status influences launch timing and interchangeability, but in established oral combination hypertension drugs, regulatory dynamics typically translate into:

• faster generic adoption once approved,
• fewer barriers to substitution at the pharmacy level.

Key practical impact:

• Once FDA-approved generic combinations are on market, prescribers and pharmacists can switch based on formularies and inventory, leading to volume shift away from the brand.

How do discounts, rebates, and copay programs affect EXFORGE net pricing?

Branded hypertension products that face generic competition rely on net-price levers:

• rebate structures with payers and PBMs,
• copay assistance to reduce patient cost-sharing,
• contracting strategies tied to volume thresholds.

Net sales outcome pattern:

• Branded units may remain on forms, but net price declines sharply post generic entry.
• Copay programs matter most in commercial settings, less so in Medicare, where patient out-of-pocket tends to be lower for generics.

What is EXFORGE’s revenue exposure by geography and payer segment?

Revenue exposure typically differs by:

• U.S. commercial (most sensitive to rebate contracting and copay programs),
• Medicare (generics drive faster cost-effective substitution),
• Medicaid (state preferred drug lists and pharmacy benefit policies).

For a mature U.S. brand like EXFORGE, the revenue base is usually concentrated in:

• patients who remain stable on the brand,
• plans where branded pricing remains competitive via contracting.

Scenario analysis: what happens to EXFORGE sales under generic acceleration?

Base-case market behavior in mature ARB+CCB:

• Each incremental generic entrant increases price competition and accelerates switching.
• Brand share stabilizes only after the bulk of patients can switch to convenient generic equivalents.

Downside scenario:

• Rapid combination-generic uptake plus PBM formulary reranking reduces branded demand more quickly than historical averages.
• Net price compression continues even if volume decline slows.

Upside scenario:

• Strong localized contracting retains preferred status longer than average.
• Clinician inertia and limited substitution in specific systems keep some brand volumes intact.

Key takeaways

• EXFORGE’s long-run financial trajectory in hypertension is primarily driven by generic erosion of the fixed-dose combination, with secondary impacts from payer tiering and net price compression.
• Market dynamics favor low-cost equivalent ARB+CCB regimens, and fixed-dose brands face rapid share loss once combination generics are available.
• Remaining branded revenue is typically sustained only by contracting strength, patient stability on therapy, and copay effectiveness in commercial insurance.
• Litigation and paragraph IV outcomes, where present, generally influence launch timing by months to a few years, not the overall direction of mature-market substitution.

FAQs

1. Does EXFORGE lose market share faster to combination generics or to separate generic valsartan plus generic amlodipine?
2. How do Medicare Part D and Medicaid preferred drug lists typically affect branded ARB+CCB combination sales?
3. What payer contracting terms usually determine whether EXFORGE stays on formulary after combination generic entry?
4. How does dosing flexibility (fixed-dose strength changes vs separate titration) influence switching from EXFORGE to generics?
5. Which endpoints (MAP reduction, tolerability, adherence) matter most for prescribers when switching from branded ARB+CCB to generics?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Drug Approval Reports and ANDA approvals (Exforge and generic equivalents). FDA.
3. Bloomberg Intelligence and industry reporting on U.S. hypertension branded-to-generic transitions (general market dynamics for ARB+CCB fixed-dose combinations).

DrugChatter Q&A for EXFORGE

Exforge hct (amlodipine besylate; hydrochlorothiazide; valsartan) drug profile, 2024?